The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents 13 years of age and older.
3 Likes
The Food and Drug Administration (FDA) has approved the supplemental New Drug Application for Rexulti (brexpiprazole) for the treatment of schizophrenia in adolescents 13 years of age and older.